Sarcoma Drugs Market

Sarcoma Drugs Market by Treatment Types (Chemotherapy and Targeted Therapy) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021-2028

  • Report ID: HC-1911
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 2
  • No. Of Pages: 182
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global sarcoma drugs market size is projected to expand at a significant CAGR during the forecast period, 2021-2028. The growth of the market is attributed to increase in the incidence of soft tissue sarcoma (STS), a rapid increase in the adoption of novel drugs, and the presence of set of automated processes to build and deploy the drugs effectively and efficiently.

Sarcoma Drugs Market key takeaways

Sarcoma refers to a type of cancer that takes place in bone or soft tissues of the body such as fibrous tissue, blood vessels, cartilage, muscle, fat, or other connective tissues. Different types of cancer are present due to the presence of different types of sarcoma. For instance, sarcoma in fats is known as liposarcoma, sarcoma in bone is known as osteosarcoma, and sarcoma in muscle is known as rhabdomyosarcoma. Sarcoma is anticipated to grow both in children and in adults and its treatment is based on the grade and type of cancer. The treatment of this type of cancer is depended upon how the cancer cell looks like when observed under a microscope and how speedily they are expected to grow and spread. It is reported that two-three people out of 100,000 are diagnosed with soft tissue sarcoma (STS) globally on an annual basis.

According to a report based on the US, 12,715 individuals were diagnosed with soft tissue sarcoma (STS) among which 5,070 death took place in 2017. Nearly 3,373 osteosarcoma cases (sarcoma in bones) were reported among which 1,649 deaths reported. The risk to develop sarcoma is 0.4% in a lifetime and in the age group but 45% of people between the age group of 0-35 years are likely to develop with osteosarcoma (sarcoma in bones) and 21% of soft tissue sarcoma (STS) are diagnosed. The only approved therapy or treatments available at present are chemotherapy and targeted therapy. Yondelis and Halaven, are two drugs developed by Johnson & Johnson and Eisai respectively for the effective treatment of cancer. Evolution in multiple phase I/II trials is done by checkpoint inhibitors (PD-1/PD-L1). Effective and safer treatment options are provided to patients when these methods are combined with standard therapies. Presently 12 out of 45 drugs are in the process of development that can be used for the treatment of osteosarcoma (bone sarcoma) and soft tissue sarcoma (STS). Several other antibodies are also under development in phase I and phase II trials.

Market Trends, Drivers, Restraints, and Opportunities

  • Introduction of Patient Assistance Programs (PAPs) that allows to cover the medical expenses for people who do not possess health insurance is a key aspect for the market growth.
  • Development and production of new drugs for sarcoma which is cost-effective and easy availability is one of the key major drivers of the market growth.
  • Increase in research and development activities and high investing from key pharmaceutical companies are anticipated to propel the growth of the market.
  • High cost of the sarcoma treatment is expected to hamper the market growth.
  • Issues regarding complex reimbursement and regulatory framework across several countries acts another restraining factor anticipated to hinder the market growth.

Scope of the Report

The report on the global sarcoma drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Sarcoma Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Treatment Types (Chemotherapy and Targeted Therapy)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Novartis; Eli Lilly, Amgen; Pfizer; Johnson & Johnson; Eisai; Bayer; ytRx; Tracon Pharma; Blueprint Medicines; Arog Pharmaceuticals; Advenchen Laboratories; and Karyopharm Therapeutics


Market Segment Insights

Chemotherapy segment is anticipated to dominate the market

On the basis of treatment types, the global sarcoma drugs market is bifurcated into chemotherapy and targeted therapy. With the introduction of targeted therapies, the market for treatment for sarcoma has immensely changed over the past few years. However, the chemotherapy segment is anticipated to dominate the market in the coming years owing to the fact that chemotherapy is highly adopted as a primary treatment procedures. It works throughout the whole body by damaging the cancer cells not only in the place where it originated but also in the place where it spreads. This fact makes chemotherapy to be the primary method for the treatment of sarcoma. The other therapies or surgery helps to remove the cancer cell or kill it at a particular place.

Sarcoma Drugs Market by treatment types

North America is expected to hold a major share of the market

In terms of regions, the global sarcoma drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North held a key share of the market and the trend is expected to continue in the coming years owing to the wide prevalence of cancer patients and high research activities for development of innovative drugs for the treatment in the region. Moreover, the presence of the key manufacturers especially in the US and rise in adoption of novel therapies for the treatment play key roles for the regional market growth. Additionally, several activities have been undertaken for the development of therapies that are patient-to-patient customized by key pharmaceutical players in the region.

Sarcoma Drugs Market by regions

Segments

Segments Covered in the Report
The global sarcoma drugs market has been segmented on the basis of

Treatment Types

  • Chemotherapy
  • Targeted Therapy

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Novartis
  • Eli Lilly
  • Amgen
  • Pfizer
  • Johnson & Johnson
  • Eisai
  • Bayer
  • Tracon Pharma
  • Blueprint Medicines
  • Arog Pharmaceuticals
  • Advenchen Laboratories
  • Karyopharm Therapeutics

Competitive Landscape

Key players competing in the global sarcoma drugs market are Novartis; Eli Lilly, Amgen; Pfizer; Johnson & Johnson; Eisai; Bayer; ytRx; Tracon Pharma; Blueprint Medicines; Arog Pharmaceuticals; Advenchen Laboratories; and Karyopharm Therapeutics. Many of these players have adopted business strategies such as launching new products, introducing new technology, merger, partnership, clinical trials, and production capacity expansion to increase their market position and expand their consumer base globally.

Sarcoma Drugs Market by key players

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Sarcoma Drugs Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Sarcoma Drugs Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Sarcoma Drugs Market - Supply Chain
  4.5. Global Sarcoma Drugs Market Forecast
     4.5.1. Sarcoma Drugs Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Sarcoma Drugs Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Sarcoma Drugs Market Absolute $ Opportunity
5. Global Sarcoma Drugs Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Sarcoma Drugs Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Sarcoma Drugs Demand Share Forecast, 2019-2026
6. North America Sarcoma Drugs Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Sarcoma Drugs Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Sarcoma Drugs Demand Share Forecast, 2019-2026
7. Latin America Sarcoma Drugs Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Sarcoma Drugs Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Sarcoma Drugs Demand Share Forecast, 2019-2026
8. Europe Sarcoma Drugs Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Sarcoma Drugs Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Sarcoma Drugs Demand Share Forecast, 2019-2026
9. Asia Pacific Sarcoma Drugs Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Sarcoma Drugs Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Sarcoma Drugs Demand Share Forecast, 2019-2026
10. Middle East & Africa Sarcoma Drugs Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Sarcoma Drugs Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Sarcoma Drugs Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Sarcoma Drugs Market: Market Share Analysis
  11.2. Sarcoma Drugs Distributors and Customers
  11.3. Sarcoma Drugs Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Novartis
     11.4.2. Eli Lilly
     11.4.3. Amgen
     11.4.4. Pfizer
     11.4.5. Johnson & Johnson
     11.4.6. Eisai
     11.4.7. Bayer
     11.4.8. Tracon Pharma

Segments Covered in the Report
The global sarcoma drugs market has been segmented on the basis of

Treatment Types

  • Chemotherapy
  • Targeted Therapy

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Novartis
  • Eli Lilly
  • Amgen
  • Pfizer
  • Johnson & Johnson
  • Eisai
  • Bayer
  • Tracon Pharma
  • Blueprint Medicines
  • Arog Pharmaceuticals
  • Advenchen Laboratories
  • Karyopharm Therapeutics

Key players competing in the global sarcoma drugs market are Novartis; Eli Lilly, Amgen; Pfizer; Johnson & Johnson; Eisai; Bayer; ytRx; Tracon Pharma; Blueprint Medicines; Arog Pharmaceuticals; Advenchen Laboratories; and Karyopharm Therapeutics. Many of these players have adopted business strategies such as launching new products, introducing new technology, merger, partnership, clinical trials, and production capacity expansion to increase their market position and expand their consumer base globally.

Sarcoma Drugs Market by key players

Buy Report